Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Quinlan Paul T, holds the title of General Counsel at Oruka Therapeutics, Inc..
On 2026-11-20, the insider transacted 18,000 shares.The shares were transacted at a weighted average price of $51.34 per share, resulting in a total market-relevant value of $924K.
Quinlan Paul T (General Counsel) sold $924K of $ORKA
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.